Analysis of TPE Treatments With multiFiltratePRO
TPEopt
1 other identifier
observational
60
1 country
3
Brief Summary
Analysis of therapeutic plasma exchange (TPE) treatments to assess the performance of the TPE mode of multiFiltratePRO based on the successful exchange of plasma from whole blood. The multiFiltratePRO is a device for extracorporeal blood purification treatments.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2024
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 5, 2024
CompletedFirst Posted
Study publicly available on registry
February 22, 2024
CompletedStudy Start
First participant enrolled
May 22, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedAugust 28, 2025
August 1, 2025
1.5 years
February 5, 2024
August 27, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Total amount of exchange plasma (prescribed vs achieved exchange volume)
Statistical analysis is performed on retrospective data (Treatments between 2019 and October 2023). Primary goal of the study is to prove that the prescribed therapeutic plasma exchange rate during treatment was achieved in \> 70% of treatments and therefore was in alignment with current guidelines.
through study completion, an average of 1 year
Study Arms (1)
TPE Treatments
Patients with indication for TPE treatment according to American Society for Apheresis (ASFA) guideline
Interventions
Retrospective Data Analysis of TPE treatments with multiFiltratePRO
Eligibility Criteria
Patients with indication for TPE treatment according to ASFA (American Society for Apheresis) guideline treated with TPE between January 2019 and October 2023.
You may qualify if:
- Body weight ≥40kg irrespective of the age
- Patients with indication for TPE treatment according to ASFA guideline
- Patients have been treated with TPE between January 2019 and October 2023
- Availability of at least 50% of the parameters to be documented for the patient
You may not qualify if:
- Participation in an interventional clinical study during the retrospectively collected TPE treatment data
- Previous documentation within this study
- Simultaneous use of another filter for additional therapy form
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Klinikum Aschaffenburg-Alzenau
Aschaffenburg, Bavaria, 63739, Germany
Universitätsklinikum Würzburg
Würzburg, Bavaria, 97080, Germany
Charité-Universitätsmedizin Berlin
Berlin, State of Berlin, 13353, Germany
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stefan Büttner, Dr. med.
Klinikum Aschaffenburg-Alzenau
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 5, 2024
First Posted
February 22, 2024
Study Start
May 22, 2024
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
August 28, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share